恒瑞医药:子公司3款药物获批临床

财中社
Aug 20

8月20日,恒瑞医药(600276/01276)发布公告,公司子公司北京盛迪、广东恒瑞及成都盛迪分别收到国家药监局核准签发的《药物临床试验批准通知书》,涉及SHR-8203注射液、SHR-7012注射液及HRS-3095片三款药物,均将于近期开展临床试验。  其中,SHR-8203注射液为公司自主研发的创新型抗肿瘤药物,拟用于治疗晚期实体瘤,国内外尚无同类药上市,累计研发投入约2040万元。  ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10